Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMYT Amryt Pharma	$14.70 +0.1%	$14.64	$6.41 ▼ $14.77	$940.21M	0.84	757,360 shs	2.39 million shs
ERGO Entia Biosciences		$0.00	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A
GRI GRI Bio	$1.42 -3.4%	$1.53	$1.10 ▼ $30.43	$3.70M	-1.61	228,320 shs	149,438 shs
SLS SELLAS Life Sciences Group	$1.70 -1.7%	$1.77	$0.77 ▼ $2.27	$182.16M	2.26	1.72 million shs	1.51 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMYT Amryt Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
ERGO Entia Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
GRI GRI Bio	+5.76%	+26.18%	-19.23%	+1.38%	-82.40%
SLS SELLAS Life Sciences Group	+6.13%	+12.34%	-2.26%	-10.82%	+31.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ERGO Entia Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	1.8013 of 5 stars	3.5	2.0	0.0	0.0	0.6	0.0	1.3
SLS SELLAS Life Sciences Group	2.8353 of 5 stars	3.5	2.0	0.0	0.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMYT Amryt Pharma	0.00	N/A	N/A	N/A
ERGO Entia Biosciences	0.00	N/A	N/A	N/A
GRI GRI Bio	3.00	Buy	$22.00	1,449.30% Upside
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	311.76% Upside

Current Analyst Ratings Breakdown

Latest AMYT, GRI, SLS, and ERGO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
6/11/2025	GRI GRI Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/27/2025	GRI GRI Bio	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $34.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMYT Amryt Pharma	$222.54M	4.22	$0.98 per share	14.98	$5.58 per share	2.63
ERGO Entia Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	$1.32 per share	N/A
SLS SELLAS Life Sciences Group	$1M	179.01	N/A	N/A	$0.25 per share	6.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMYT Amryt Pharma	$1M	-$0.06	N/A	735.00	N/A	-8.19%	1.70%	0.75%	N/A
ERGO Entia Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	-$8.21M	-$11.56	0.00	N/A	N/A	N/A	-327.62%	-191.40%	N/A
SLS SELLAS Life Sciences Group	-$30.88M	-$0.32	0.00	N/A	N/A	N/A	-132.51%	-92.79%	N/A

Latest AMYT, GRI, SLS, and ERGO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	GRI GRI Bio	-$1.31	-$1.31	N/A	-$1.31	N/A	N/A
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	-$0.07	+$0.0067	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A
ERGO Entia Biosciences	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMYT Amryt Pharma	0.64	1.57	0.94
ERGO Entia Biosciences	N/A	N/A	N/A
GRI GRI Bio	N/A	2.41	1.41
SLS SELLAS Life Sciences Group	N/A	4.91	4.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMYT Amryt Pharma	71.31%
ERGO Entia Biosciences	N/A
GRI GRI Bio	33.95%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
AMYT Amryt Pharma	5.66%
ERGO Entia Biosciences	28.30%
GRI GRI Bio	0.87%
SLS SELLAS Life Sciences Group	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMYT Amryt Pharma	2,020	63.96 million	60.34 million	Not Optionable
ERGO Entia Biosciences	6	N/A	N/A	Not Optionable
GRI GRI Bio	1	2.52 million	2.49 million	Not Optionable
SLS SELLAS Life Sciences Group	10	105.30 million	104.03 million	Not Optionable

AMYT, GRI, SLS, and ERGO Headlines

Recent News About These Companies

SELLAS Life Sciences Group (NASDAQ:SLS) Issues Earnings Results

August 14, 2025 | marketbeat.com

Sellas Life Sciences Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

Sellas Life Sciences reports Q2 EPS (7c), consensus (8c)

August 12, 2025 | msn.com

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | finance.yahoo.com

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ...

August 9, 2025 | finance.yahoo.com

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

August 7, 2025 | globenewswire.com

SELLAS Life Sciences Group (SLS) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

July 31, 2025 | zacks.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 1.8% - What's Next?

July 31, 2025 | marketbeat.com

Sellas Flat on Trial Success

July 16, 2025 | baystreet.ca

SELLAS gains as mid-stage trial for leukemia drug succeeds

July 16, 2025 | msn.com

SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - Nasdaq

July 9, 2025 | nasdaq.com

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

July 7, 2025 | msn.com

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

July 7, 2025 | globenewswire.com

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14, 2025 | insidertrades.com

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

June 5, 2025 | globenewswire.com

SELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025

June 4, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AMYT, GRI, SLS, and ERGO Company Descriptions

Amryt Pharma NASDAQ:AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Entia Biosciences OTCMKTS:ERGO

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.

GRI Bio NASDAQ:GRI

$1.42 -0.05 (-3.40%)

As of 04:00 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

SELLAS Life Sciences Group NASDAQ:SLS

$1.70 -0.03 (-1.73%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 0.00 (0.00%)

As of 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time